Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00678106 · ClinicalTrials.gov registry record · Phase 1
Study Of Dalbavancin Drug Levels Achieved In Hospitalized Adolescents Who Are Receiving Antibiotic Therapy For Bacterial Infections
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT00678106 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 10 participants.
The verdict
NCT00678106, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
Adolescent subjects hospitalized for the treatment of bacterial infections will be given 1 gram of dalbavancin through their veins and levels of dalbavancin in blood and urine will be measured at different time points. Safety labs will also be checked on a regular basis to assess the safety of dalbavancin.
Interventions
- DRUG Dalbavancin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2008-09 |
| Est. Completion | 2009-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00678106
The ClinicalTrials.gov registry entry for NCT00678106 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dalbavancin is the first listed.
NCT00678106 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00678106 about?
NCT00678106 is a clinical study titled "Study Of Dalbavancin Drug Levels Achieved In Hospitalized Adolescents Who Are Receiving Antibiotic Therapy For Bacterial Infections". Adolescent subjects hospitalized for the treatment of bacterial infections will be given 1 gram of dalbavancin through their veins and levels of dalbavancin in blood and urine will be measured at different time points. Safety labs will also be checked on a regular basis to assess the safety of dalba...
What is the current status of trial NCT00678106?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2008-09. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00678106?
The interventions under investigation include: Dalbavancin (DRUG).
Who is sponsoring clinical trial NCT00678106?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.